Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.34 |
| ▸ | GLA | P06280 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | EGFR | P00533 | 3/20 | 0.32 |
| ▸ | RCE1 | Q9Y256 | 1/20 | 0.32 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.32 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.32 |
| ▸ | NR1I3 | Q14994 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6764344 | 1.00 | LMNA (0.36) | LMNAKDM4EPDE4DGLATP53 | |
| SCHEMBL6757213 | 0.90 | MTNR1B (0.38) | LMNAKDM4EHTT | |
| SCHEMBL6757217 | 0.90 | MTNR1B (0.38) | LMNAKDM4EHTT | |
| SCHEMBL6757231 | 0.87 | MAPT (0.39) | GLAPOLBSMN1; SMN2MAPTEGFR | |
| SCHEMBL6757233 | 0.87 | MAPT (0.39) | GLAPOLBSMN1; SMN2MAPTEGFR | |
| SCHEMBL6761534 | 0.84 | LMNA (0.41) | LMNAKDM4EPDE4DGLAPOLB | |
| SCHEMBL6761535 | 0.84 | LMNA (0.41) | LMNAKDM4EPDE4DGLAPOLB | |
| SCHEMBL6760921 | 0.82 | LMNA (0.36) | LMNAKDM4EPDE4DGLASMN1; SMN2 | |
| SCHEMBL6760922 | 0.82 | LMNA (0.36) | LMNAKDM4EPDE4DGLASMN1; SMN2 | |
| SCHEMBL6760914 | 0.81 | LMNA (0.39) | LMNAPDE4DGLAPOLBMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040106635-A1 | having small-conductance potassium channel (SK) blocking activity | TANABE SEIYAKU CO., LTD. (JP) | 2004-06-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040106635-A1 | having small-conductance potassium channel (SK) blocking activity | KCNN1, KCNN2, KCNN3 | LMNA 612/4885KDM4E 1346/4885PDE4D 2101/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.